The Tasly agreement is for the heart products (MPC-based, not MSC-based). From the latest half yearly report:
Extending the existing partnership with Tasly to include MSC product/s (Restemcel-L/Ryoncil) is an obvious potential move. However, judging by the lack of progress in the existing partnership, I'm not holding my breath...
I'm surprised JCR/Temcell hasn't been mentioned as about the easiest way to get the equivalent of Ryoncil into COVID-19 ARDS trials. Already approved in Japan and being commercially manufactured by JCR (not sure on what scale). Just needs a mates agreement to licence for ARDS. Maybe not enough sufferers in Japan to get sufficient patients for a trial?
Here's the latest (*******), page-32
Add MSB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.15 |
Change
0.045(4.07%) |
Mkt cap ! $1.313B | |||
| Open | High | Low | Value | Volume |
| $1.08 | $1.16 | $1.08 | $4.681M | 4.170M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 99680 | $1.15 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.16 | 31000 | 2 |
View Market Depth
| Last trade - 16.10pm 19/07/2024 (20 minute delay) ? |
| MSB (ASX) Chart |